HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded by Quitadamo, Briana et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Program in Molecular Medicine Publications 
and Presentations Program in Molecular Medicine 
2018-01-02 
HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind 
CD4 with High Affinity, while the CD4 Binding Site on Non-
macrophage-tropic, T-Tropic R5 Envelopes Is Occluded 
Briana Quitadamo 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/pmm_pp 
 Part of the Biochemistry Commons, Immunology of Infectious Disease Commons, 
Immunoprophylaxis and Therapy Commons, Molecular Biology Commons, Molecular Genetics Commons, 
Virology Commons, and the Viruses Commons 
Repository Citation 
Quitadamo B, Peters PJ, Repik A, O'Connell O, Mou Z, Koch M, Somasundaran M, Brody RM, Luzuriaga K, 
Wallace A, Wang S, Lu S, McCauley SM, Luban J, Duenas-Decamp MJ, Gonzalez-Perez MP, Clapham PR. 
(2018). HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the 
CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded. Program in Molecular 
Medicine Publications and Presentations. https://doi.org/10.1128/JVI.00841-17. Retrieved from 
https://escholarship.umassmed.edu/pmm_pp/87 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Program in Molecular 
Medicine Publications and Presentations by an authorized administrator of eScholarship@UMMS. For more 
information, please contact Lisa.Palmer@umassmed.edu. 
HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers
Bind CD4 with High Afﬁnity, while the CD4 Binding Site on
Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded
Briana Quitadamo,a Paul J. Peters,a* Alexander Repik,a Olivia O’Connell,a Zhongming Mou,a Matthew Koch,a
Mohan Somasundaran,a Robin Brody,a Katherine Luzuriaga,a Aaron Wallace,b* Shixia Wang,b Shan Lu,b Sean McCauley,a
Jeremy Luban,a Maria Duenas-Decamp,a Maria Paz Gonzalez-Perez,a Paul R. Claphama
aProgram in Molecular Medicine, University of Massachusetts Medical School, Biotech 2, Worcester,
Massachusetts, USA
bDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
ABSTRACT HIV-1 R5 variants exploit CCR5 as a coreceptor to infect both T cells
and macrophages. R5 viruses that are transmitted or derived from immune tissue
and peripheral blood are mainly inefﬁcient at mediating infection of macrophages.
In contrast, highly macrophage-tropic (mac-tropic) R5 viruses predominate in brain
tissue and can be detected in cerebrospinal ﬂuid but are infrequent in immune tis-
sue or blood even in late disease. These mac-tropic R5 variants carry envelope gly-
coproteins (Envs) adapted to exploit low levels of CD4 on macrophages to induce
infection. However, it is unclear whether this adaptation is conferred by an increased
afﬁnity of the Env trimer for CD4 or is mediated by postbinding structural rearrange-
ments in the trimer that enhance the exposure of the coreceptor binding site and
facilitate events leading to fusion and virus entry. In this study, we investigated CD4
binding to mac-tropic and non-mac-tropic Env trimers and showed that CD4-IgG
binds efﬁciently to mac-tropic R5 Env trimers, while binding to non-mac-tropic trim-
ers was undetectable. Our data indicated that the CD4 binding site (CD4bs) is highly
occluded on Env trimers of non-mac-tropic R5 viruses. Such viruses may therefore
infect T cells via viral synapses where Env and CD4 become highly concentrated.
This environment will enable high-avidity interactions that overcome extremely low
Env-CD4 afﬁnities.
IMPORTANCE HIV R5 variants bind to CD4 and CCR5 receptors on T cells and mac-
rophages to initiate infection. Transmitted HIV variants infect T cells but not macro-
phages, and these viral strains persist in immune tissue even in late disease. Here
we show that the binding site for CD4 present on HIV’s envelope protein is oc-
cluded on viruses replicating in immune tissue. This occlusion likely prevents anti-
body binding to this site and neutralization of the virus, but it makes it difﬁcult for
virus-CD4 interactions to occur. Such viruses probably pass from T cell to T cell via
cell contacts where CD4 is highly concentrated and allows infection via inefﬁcient
envelope-CD4 binding. Our data are highly relevant for vaccines that aim to induce
antibodies targeting the CD4 binding site on the envelope protein.
KEYWORDS CCR5, CD4, CD4bs, HIV, envelope glycoprotein, macrophage tropism
The HIV-1 envelope glycoprotein (Env) on viral particles is arranged as trimers withthree copies of surface gp120 and three of transmembrane gp41. HIV infection of
cells requires interactions between Env trimers on virus particles with CD4 and a
coreceptor, either CCR5 or CXCR4, on the cell surface. These interactions trigger fusion
between viral and cell membranes, initiating virus entry (reviewed in reference 1).
HIV-1 R5 Envs exploit CCR5 as a coreceptor to infect both T cells and macrophages.
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R5 Envs derived from immune tissue (e.g., lymph node and spleen) and from peripheral
blood are inefﬁcient at mediating infection of macrophages. These Envs have been
described as R5, non-macrophage tropic (non-mac tropic) (2, 3), or R5, T-cell tropic (4).
In contrast, highly mac-tropic R5 Envs are predominant in brain tissue and detected in
cerebrospinal ﬂuid (CSF) (4, 5). Mac-tropic R5 variants have also been detected in semen
(3, 6, 7) but are infrequent in immune tissue or blood even in late disease (3).
On virus particles in vivo, native and unliganded Env trimers predominantly form a
closed conformation with the three gp120s connecting at the apex via the trimer
association domain (TAD), which is comprised of the V1V2 and V3 loops (8–14). When
CD4 on the cell surface binds an HIV-1 Env spike, it triggers the Env trimer to open and
expose a site for binding a coreceptor, usually CCR5 (15). Trimer opening involves the
disentanglement of the TAD to enable (i) a shift in the location of the V1V2 loops to
expose the V3 loop and (ii) exposure of a determinant on the V1V2 stem that is
recruited by CD4 to assemble the bridging sheet. The V3 loop and sections of the
bridging sheet form the exposed coreceptor binding site (1). We previously reported
that over 50% of highly, mac-tropic Envs carried modiﬁed TADs, estimated either by
increased V3 loop exposure or by loss of the PG9/16 trimer-speciﬁc epitope on V1V2 of
the TAD (16). All Envs remained resistant to neutralization by CD4i (CD4-induced)
monoclonal antibodies (MAbs) and the CD4 binding site (CD4bs) MAb, b6, indicating
that mac-tropic trimers are not wide open but have subtle changes in the TAD that
allow CD4 access to the CD4bs or enable the trimer to open more efﬁciently on
encountering CD4. On the native trimer, the conﬁguration of the trimer association
domain and glycans that are within it and nearby play an important role in protecting
the CD4bs from antibodies (17).
Mac-tropic R5 Envs have adapted to be able to interact efﬁciently with low CD4
levels to trigger conformational changes in the Env trimer that expose the CCR5
binding site. This enhanced Env-CD4 interaction allows the infection of macrophages,
which express substantially smaller amounts of CD4 on their cell surfaces than do T cells
(18–20). No speciﬁc Env determinant has been identiﬁed that universally explains R5
mac tropism. The Gabuzda lab identiﬁed N283 (a CD4bs residue) as present in mac-
tropic or brain-derived Envs of some subjects that showed enhanced gp120-CD4
interactions (21). However, other determinants have been identiﬁed proximal to the
CD4bs (22) and within the V1 (23), V2 (24), and V3 (22) loops. It seems likely that any
Env determinant that enhances the exposure of the CD4bs will result in an enhanced
Env-CD4 interaction and increased macrophage infection. Such determinants may
occur in different regions of Env, and it is likely that different determinants in different
Envs impact mac tropism. It is also unclear whether the capacity of Env to exploit low
CD4 concentrations to trigger entry results from a more efﬁcient initial binding
event between Env and CD4, enhanced Env trimer conformational changes in
response to CD4 binding, or both. Thus, while several studies have investigated the
capacity of R5 mac-tropic and non-mac-tropic viruses to exploit low CD4 to infect
cells, none have directly measured or compared CD4 binding to trimeric, native
Envs of such variants.
In this study, we investigated CD4 binding to mac-tropic and non-mac-tropic Env
trimers expressed on 293T cells. We show that CD4-IgG binds efﬁciently to mac-tropic
R5 Env trimers, while binding to non-mac-tropic trimers was remarkably inefﬁcient or
undetectable. This nearly undetectable binding of CD4 to non-mac-tropic Envs pre-
sumably reﬂects an adaptation to protect this site from antibodies but at a cost of
compromising Env-CD4 binding. Nevertheless, this observation for non-mac-tropic Env
trimers is remarkable considering that all HIV-1 variants must bind CD4 to gain entry
into cells. Our data may therefore point toward a preferred route of entry into T cells
for non-mac-tropic R5 viruses across viral synapses where Env and CD4 become highly
concentrated (25, 26) and thus enable high-avidity interactions that can overcome
extremely low Env-CD4 afﬁnities.
Quitadamo et al. Journal of Virology
January 2018 Volume 92 Issue 2 e00841-17 jvi.asm.org 2
 o
n
 M
ay 29, 2018 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
RESULTS
Trimeric mac-tropic Envs bind CD4-IgG efﬁciently, while binding for non-mac-
tropic Envs is barely detectable. (i) Expression of HIV-1 Envs on 293T cells and
CD4-Ig binding. We investigated the capacity of CD4-IgG to bind to trimeric Envs
expressed on the surface of 293T cells. We expressed mac-tropic B33, B59, and JRFL and
non-mac-tropic LN40, LN8, and JRCSF Envs on 293T cells and tested CD4-Ig binding (10
g/ml). Envs in pSVIIIenv were cotransfected with pSV2-tat 72 and the furin expression
vector pFurin into 293T cells (27). Overexpression of furin facilitates Env cleavage and
the production of functional trimers (27). Env expression was modest but readily
detected by MAbs and was quantiﬁable using ﬂow cytometry. Figure 1A (left three
FIG 1 Trimeric Env binding to CD4-Ig. (A) Binding of CD4-Ig to Env trimers expressed on 293T cells measured by ﬂow cytometry (left three graphs). Three Env
pairs from different subjects were analyzed: B33 and LN40, B59 and LN8, and JRFL and JRCSF. Results for Envs from each pair were plotted in each of the three
graphs presented, and each included a mac-tropic (B33, B59, or JRFL) and non-mac-tropic (LN40, LN8, or JRCSF) Env. Duplicate ﬂow cytometry proﬁles for each
Env are presented. CD4-Ig (10 g/ml) binding to B33, B59, and JRFL Env trimers was readily detected. Binding to non-mac-tropic R5 Envs was at background
levels. The rightmost graphs show mean ﬂuorescence values plotted from data shown in the ﬂow cytometry proﬁles. Boxed values at the bottom of each graph
show CD4-Ig neutralization values (50% inhibitory concentrations [IC50s], in micrograms per milliliter) of the equivalent Env pseudoviruses. Horizontal arrows
indicate the three Env pairs from three different patients. Vertical arrows indicate ﬂuorescence measurements that were too low to register on the relevant
graph. (B) All Envs bound efﬁciently to MAb PGT128, conﬁrming efﬁcient expression of both mac-tropic and non-mac-tropic Envs (left three graphs). The
rightmost graphs show mean ﬂuorescence values, with boxed values at the bottom of each graph indicating PGT128 neutralization titers of the equivalent Env
pseudoviruses as described for panel A. (C) Soluble CD4 binding to NA420 B33 and LN40 Envs, conﬁrming that binding was similar to that observed for CD4-Ig
as shown in panel A.
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graphs) shows that mac-tropic Envs B33, B59, and JRFL bound efﬁciently to CD4-Ig,
while for non-mac-tropic Envs LN40, LN8, and JRCSF, binding was at best very weak or
undetectable. In contrast to CD4-Ig binding, all six Envs bound MAb PGT128, indicating
that the lack of CD4-Ig binding for non-mac-tropic LN40, LN8, and JRCSF was not due
to lack of expression (Fig. 1B, left three graphs). Of note, CD4-Ig and PGT128 binding to
Envs on 293T cells broadly tracked with Env sensitivity to inhibition or neutralization by
these reagents using Env pseudoviruses carrying each of the six Envs (Fig. 1, rightmost
graphs, where ﬂow binding measurements are summarized, along with inhibition or
neutralization titers). The only exception was JRCSF, which was neutralized by CD4-Ig
with modest sensitivity, even though CD4-Ig binding to Envs expressed on 293T cells
was at background levels.
Experiments so far tested CD4-Ig binding to Envs on 293T cells. CD4-Ig carries two
D1D2 domains on CD4 and is thus dimeric (28). We next conﬁrmed that monomeric
soluble CD4 (sCD4) binding to Env trimers followed the same pattern of binding to
293T expressed Envs. We used B33 mac-tropic and LN40 non-mac-tropic Envs (Fig. 1C)
and observed highly efﬁcient binding to mac-tropic B33 but only background binding
to non-mac-tropic LN40 Env, observations that parallel those for CD4-Ig (Fig. 1A,
leftmost graph).
(ii) Expression of HIV-1 Envs on 293T cells and binding of a panel of human
MAbs.We next tested Env binding to a further panel of eight MAbs to conﬁrm efﬁcient
expression of each Env and to assess the presence of cleaved, native trimers. We
wanted to compare MAb binding to each Env expressed on 293T cells, with neutral-
ization titers obtained using Env pseudoviruses to assess how closely 293T expressed
Envs represented functional Envs on pseudoviruses. Flow cytometry proﬁles of MAb
binding to each Env are presented in the left three graphs in each panel of Fig. 2, while
a summary graph of binding measurements compared to neutralization is shown in the
rightmost graphs. All Envs bound and were neutralized by 2G12 except B33, which
lacks the glycan epitope for this MAb (29) (Fig. 2A). Env binding to trimer apex MAbs
PG9 and PGT145 also followed the sensitivity of Env pseudoviruses to neutralization
(Fig. 2B and C). For example, non-mac-tropic Envs LN8 and JRCSF were efﬁciently
bound by and neutralized by PG9 and PGT145, while LN40 (which lacks the N160 glycan
required for binding [30]) did not bind these MAbs and was resistant to neutralization
by them.
Only B33 Env bound V3 MAb 447-52D, and B33 is the only Env sensitive to
neutralization by this MAb, thus conﬁrming exposure of the V3 loop crown (16)
(Fig. 2D). None of the Envs bound the CD4i MAb 17b on 293T cells, and all were
resistant to neutralization by this MAb, consistent with the occlusion of CD4i and
coreceptor binding site on native trimeric Envs (Fig. 2E).
Env binding to CD4bs MAbs VRC01, b12, and b6 was also tested (Fig. 2F to H). All
Envs bound and were neutralized by VRC01, as expected for this broadly neutralizing
antibody (31). However, b12 preferentially bound mac-tropic Envs that were sensitive
to neutralization by this MAb (16). In contrast, none of the Envs efﬁciently bound or
were neutralized by MAb b6, which is protected within primary trimeric Envs (16, 27).
For most MAbs and Envs, binding measured by ﬂow (mean ﬂuorescence) correlated
with neutralization or inhibition titer (Table 1), although correlations were not apparent
for CD4-Ig or MAbs b12 and PGT128. Nevertheless, whenever MAb binding was strong
by ﬂow, there was also sensitive neutralization. These data therefore support the
expression of native Env trimers on 293T cells that mimic those present on virus
particles during cell entry. There were a small number of exceptions, where binding and
neutralization measurements were conﬂicting. These included CD4-Ig and JRCSF Env,
where modest inhibition was apparent, but binding to Env 293T cells was at best
weak. Similarly, MAb b12 neutralized LN8, while binding to LN8 Env on 293T cells was
very weak. The explanation for these discrepancies is unclear. There may be some
situations where Env processing during and after the budding of virions alters the
exposure of some epitopes (32–34). Alternatively, it is possible that the CD4bs on JRCSF
Quitadamo et al. Journal of Virology
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FIG 2 Flow cytometry showing MAb binding to Env trimers expressed on 293T cells. Human MAb binding to mac-tropic and non-mac-tropic R5
Env pairs: B33 and LN40, B59 and LN8, and JRFL and JRCSF. MAbs tested were 2G12 (A), PG9 (B), PG145 (C), 447-52D (D), 17b (E), VRC01 (F), b12
(G), and b6 (H). Duplicate ﬂow cytometry proﬁles for each Env and MAb are presented. The rightmost graphs show mean ﬂuorescence values
plotted from data shown in the ﬂow cytometry proﬁles. Boxed values at the bottom of each graph show CD4-Ig neutralization of the equivalent
Env pseudoviruses. Horizontal arrows indicate the three Env pairs from three different patients. Vertical arrows indicate ﬂuorescence
measurements that were too low to register on the relevant graph. MAb binding to trimers broadly tracked neutralization sensitivity, consistent
with the expression and detection of functional Env trimers expressed on 293T cells (Table 2).
The CD4bs on HIV-1 Non-mac-tropic R5 Envs Is Occluded Journal of Virology
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and the b12 epitope on LN8 become available at an undeﬁned stage during entry into
cells, allowing CD4-Ig and b12 to neutralize, respectively.
(iii) CD4 and MAb binding to soluble gp120. Undetectable binding of CD4-Ig to
non-mac-tropic Env trimers is curious considering that these Envs routinely confer
infection of CD4 cells where entry can be blocked by CD4-speciﬁc MAbs (35). To
conﬁrm that the Envs used in this current study bound CD4, we expressed gp120 in
FIG 2 (Continued)
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soluble form and assessed binding to CD4-Ig using a Fortebio Octet QKe platform.
Results presented in Table 2 indicate that both mac-tropic and non-mac-tropic Envs
bound CD4-Ig to high afﬁnity in the low nanomolar range. Mac-tropic B33 and B59
gp120s conferred slightly higher afﬁnities than did non-mac-tropic LN40 and LN8
gp120s, which were derived from subjects NA420 and NA20, respectively. In contrast,
equilibrium dissociation constants (KDs) for gp120s from JRFL and JRCSF were not
signiﬁcantly different.
The lack of MAb binding to Envs expressed on 293T cells (Fig. 2) may result from the
occlusion of the target epitopes within the trimer, or simply because the epitope is
absent. This is an important issue for MAbs 447-52D, b12, b6, and 17b, because we are
arguing that the epitopes for these MAbs are occluded within the trimer for the Envs
that they do not bind. Previously, we used enzyme-linked immunosorbent assays
(ELISAs) to test whether MAbs 447-52D and b12 bound to soluble gp120 derived from
each of the Envs investigated in this work (16) and have now also tested MAbs 17b and
b6 (data summarized in Table 2). We showed strong binding of both b6 and 17b (in the
presence of sCD4) to gp120 by ELISAs. Together, these data show that all four MAbs
bound to gp120s of all six Envs. The only exception was 17b binding to LN8 gp120,
which was weak. This control experiment conﬁrms that all six Envs under study carried
b6, 17b, 447-52D, and b12 epitopes and supports the view that the lack of trimer
binding for these MAbs is due to the occlusion of their epitopes. Again, these data
support the expression of native, cleaved trimers rather than other Env products where
the epitopes of these MAbs are potentially exposed.
(iv) Titration of CD4-IgG binding to mac-tropic and non-mac-tropic R5 Envs on
293T cells. We tested whether CD4-IgG binding to mac-tropic Envs expressed on 293T
cells could be titrated out. For this experiment, we tested B33 and LN40 along with JRFL
TABLE 1 Correlations between binding and neutralization by CD4-Ig and MAbs to Envs
expressed on 293T cells
MAb Epitope(s)
Correlation
between binding
and neutralization
P value Signiﬁcance
CD4-Ig CD4bs 0.19
PGT128 V3/glycans 0.26
2G12 Glycans 0.035 *
PG9 TAD apex 0.008 **
PGT145 TAD apex 0.016 *
447-52D V3 loop 0.032 *
VRC01 CD4bs 0.01 **
b12 CD4bs 0.4726
b6 CD4bs —a —
17b CD4i — —
aA dash indicates that the antibody showed no binding and no neutralization. *, P  0.05; **, P  0.01.
TABLE 2 Soluble CD4 binding to CD4-Ig and human monoclonal antibodiesa
aCD4-Ig binding to soluble gp120 was measured by the ForteBio Octet QKe platform (shown as KDs). MAb
binding to gp120 was measured by ELISAs (shown as half-maximal effective concentrations [EC50]). 1, color
coding is as follows: red, 0.01 g/ml; yellow, 0.01 to 0.1 g/ml; orange, 0.1 to 1 g/ml; and blue, 1 g/
ml. 2, 17b tested in the presence of sCD4 (3 g/ml).
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and JRCSF, two Env pairs from subjects NA420 and JR, respectively (2, 3, 36). We also
tested additional mac-tropic Envs, B93 and CA110 1-2, from brain tissue of subjects
NA176 and CA110, respectively, as well as a non-mac-tropic Env, LN33, from lymph
node tissue of subject NA118 (2, 37). The highest concentration of CD4-Ig tested was
10 g/ml since higher concentrations resulted in an increase in nonspeciﬁc background
staining.
Figure 3 shows binding curves for each Env. For each of the four mac-tropic Envs,
CD4-Ig binding could be titrated out, with positive staining still detectable at between
0.3 and 0.6 g/ml of CD4-Ig (Fig. 3). In contrast, CD4-IgG binding to non-mac-tropic
Envs, LN40 and LN33, was not detected even at 10 g/ml, while binding to JRCSF was
low to background across several CD4-Ig concentrations, including 10 g/ml. We were
unable to measure half-maximal binding of CD4-Ig concentrations for mac-tropic Envs,
since it was unclear whether maximal binding had been achieved at 10 g/ml.
In summary, CD4-IgG bound efﬁciently to mac-tropic R5 Envs expressed on 293T
cells, while binding to non-mac-tropic Envs was at best barely detectable. Binding to
mac-tropic R5 Envs was at least 15- to 30-fold higher than for non-mac-tropic Envs.
Soluble CD4 treatment of non-mac-tropic LN8 Env does not modulate the V2q
(PGT145) epitope or expose the V3 loop crown. It seemed surprising that CD4-IgG
FIG 3 Titration of CD4-Ig binding to Env trimers. CD4-Ig binding to mac-tropic and non-mac-tropic R5
Envs was titrated out. Mac-tropic B33, JRFL, B93, and CA110 1-2 Env binding to CD4-Ig was detectable
at 1 g/ml, while binding to non-mac-tropic Envs LN40 and LN33 was undetectable at 10 g/ml.
However, weak, low-level binding of CD4-Ig to non-mac-tropic JRCSF was apparent.
Quitadamo et al. Journal of Virology
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(10 g/ml) binding to non-mac-tropic R5 Env trimers was not reliably detected,
considering that all primary HIV-1 Envs require cell surface CD4 to trigger entry.
However, non-mac-tropic R5 Env viruses are also generally resistant to inhibition by
sCD4, which could be consistent with a lack of binding. However, it is also possible that
sCD4 may bind to non-mac-tropic Envs and initiate conformational changes that fail to
complete and result in sCD4 falling off. In this situation, it should be possible to observe
changes in the TAD structure in the presence of sCD4. To test this, we investigated
whether sCD4 treatment of pseudoviruses carrying non-mac-tropic LN8 Envs modu-
lated the PGT145 (TAD, V2q) or 447-52D (V3) epitopes on Env. These two MAbs were
appropriate for this experiment since we had previously shown that LN8 Env pseu-
doviruses were highly sensitive to PG9/PG16-type MAbs (16). In contrast, while LN8
gp120 bound 447-52D with an extremely low half-maximal effective concentration
(EC50) (Table 2), Env pseudoviruses were resistant to neutralization. If sCD4 could bind
to LN8 Envs and induce conformational changes in the trimer, we would expect to
observe loss of the PGT145 epitope and, at the same time, exposure of the V3 loop and
447-52D epitope. Figure 4A shows that LN8 Env pseudovirions remained sensitive to
PGT145 and resistant to 447-52D MAbs even in the presence of 25 g/ml of sCD4. We
also conﬁrmed that sCD4 failed to modulate the PGT145 epitope on both LN8 and
JRCSF by testing MAb binding to trimers expressed on 293T cells (Fig. 4B). In contrast,
sCD4 signiﬁcantly reduced PGT145 binding to mac-tropic B59 Env trimers. Together,
these results are consistent with a lack of sCD4 binding to LN8 and JRCSF Env trimers
and support the lack of binding by CD4-IgG observed in the trimer binding assay (Fig.
1 and 3).
DISCUSSION
We demonstrate that mac-tropic R5 Env trimers have higher afﬁnity for CD4 than do
non-mac-tropic R5 Envs. Remarkably, CD4 binding for non-mac-tropic Envs trimers
FIG 4 High concentrations of sCD4 do not modulate trimer association domain MAb PGT145 or V3 crown MAb 447-52D
epitopes on R5 non-mac-tropic Env LN8. (A) (Left) The high sensitivity of LN8 Env pseudoviruses to MAb PGT145
neutralization was not affected by pretreatment and the presence of 25 g/ml sCD4. (Right) Pretreatment and the
presence of 25 g/ml of sCD4 failed to expose the 447-52D epitope on the V3 crown of LN8. (B) Soluble CD4 (20 g/ml)
failed to modulate the PGT145 TAD epitope on non-mac-tropic Envs LN8 (left) and JRCSF (right), consistent with the lack
of CD4 binding. In contrast, sCD4 downregulated the PGT145 epitope for mac-tropic Env B59 (middle), consistent with CD4
binding and TAD opening. Note that the 447-52D epitope is present on LN8 Env but occluded on the trimer (16).
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derived from lymph node tissue was undetectable despite high-afﬁnity binding of CD4
by soluble gp120s from the same Envs. Together, these data indicate that the CD4bs on
non-mac-tropic R5 Env trimers from immune tissue is occluded, presumably to protect
against binding of CD4bs antibodies. These data conﬁrm for native trimeric Envs several
previous observations that implied a higher CD4 afﬁnity for mac-tropic Envs, including
(i) infection of cells carrying low levels of CD4 (2, 3, 5, 24, 38), (ii) high sensitivity to
inhibition by sCD4 (35), (iii) determinants of mac tropism within or proximal to the
CD4bs (21, 22), and (iv) a higher gp120-CD4 afﬁnity for mac-tropic Envs carrying N283
determinant in the CD4bs (21).
Expression of HIV-1 Envs on 293T and other cell types results in several nonfunc-
tional forms of Env reaching the cell surface. These include uncleaved gp160 trimers
(39–41), soluble forms of gp160 (42, 43), gp41 stumps (42), and shed gp120 monomers
(44, 45). We investigated binding of Envs expressed on 293T cells to a panel of nine Env
MAbs previously used to evaluate overall Env expression and the presence of mature,
cleaved trimers (27). Brieﬂy, the lack of binding by the CD4bs MAb, b6, supports the
presence of closed and cleaved trimers since this MAb binds a CD4bs epitope that is
protected within mature trimers but would be exposed on gp120 monomers and
uncleaved Envs. Similarly, the lack of binding by CD4i MAb 17b supports the presence
of untriggered trimers. In addition, binding of the different MAbs tracked closely to
neutralization data supporting the presence of functional trimers. Of note, the lack of
CD4-IgG binding to non-mac-tropic Envs also supports the presence of cleaved trimers
for these Envs, since uncleaved Envs, monomers and/or defective Envs would be
expected to carry a more exposed CD4bs and to bind CD4-IgG more efﬁciently (27).
Our study is based on a relatively small sample of mac-tropic and non-mac-tropic R5
Envs. However, we expect that the results presented on Env-receptor interactions will
apply to many Envs of these tropisms. This is because our previous studies on many
other such Envs have shown a clear consistency on sensitivity to reagents that block or
inhibit Env-receptor interactions, including sCD4 and CD4-Ig and anti-CD4 MAbs and
CCR5 antagonists (2, 3, 16, 30, 35, 37, 46). Together, these studies indicate that
mac-tropic and non-mac-tropic Env groups each share their own common receptor
binding characteristics.
Non-mac-tropic Env trimers did not convincingly bind CD4-Ig or sCD4. We expressed
soluble gp120 from these Envs and conﬁrmed that they bound CD4-Ig with high
afﬁnity. For this experiment, we used gp120 preparations produced on 293T cells that
had been puriﬁed via lectin columns. This approach enabled multiple gp120 prepara-
tions to be produced routinely. However, Coutu and Finzi recently reported that soluble
gp120 produced from 293T cells frequently contained unnatural dimers that affect
estimates of gp120-CD4 afﬁnities providing low measurements (47). The gp120
preparations used in this study contained variable amounts of dimers, from unde-
tectable to just modest levels (data not shown). Regardless, each gp120 tested
bound CD4 with high afﬁnity, conﬁrming that the non-mac-tropic Envs carried the
potential to bind CD4.
Weak or undetectable binding of CD4 for non-mac-tropic R5 Envs is remarkable.
How do these non-mac-tropic Envs trigger infection of CD4 T cells if CD4 binding is
so inefﬁcient? CD4 T cells carry high concentrations of CD4 (20), which may help
compensate. However, non-mac-tropic Env viruses may preferentially infect via viro-
logical synapses where both CD4 and CCR5 become highly concentrated on the T-cell
target membrane present in synapses, while Env is concentrated on the membrane of
the infected cell. Previously, we reported that trans-infection of CD4 T cells across
synapses by virus captured by monocyte-derived dendritic cells preferentially sup-
ported infection by non-mac-tropic Env pseudoviruses, consistent with this hypoth-
esis (26). It is therefore likely that the high density of Envs meeting a high density of
receptors in the synapse enables high-avidity interactions that can overcome low
Env-CD4 afﬁnities.
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MATERIALS AND METHODS
Envelope clones. Full-length HIV-1 Env clones were expressed from pSVIIIenv or from Rev-Env
inserts in pcDNA3.1 as previously reported (16). JRFL and JRCSF Env clones were codon optimized and
expressed from pcDNA3.1.
gp120s were expressed from pJW4303 as previously described (16, 48). gp120 sequences were
cloned into pJW4303 downstream of the tissue plasminogen activator (tPA) leader sequence.
The GenBank accession numbers for envelopes used are as follows: NA420 B33, GU724973; NA420
LN40, GU724974; NA20 B59, HM014318; NA20 LN8, HM014322; JRFL, U63632; JRCSF, AY426126; NA118
LN33, HM771419; and CA110 1-2, MF975654.
Cells. Cells used have all been described previously and included HeLa TZM-bl (49) and 293T and
293F (50–52) cells.
Authentication of cell lines. HeLa TZM-bl cells were obtained from the NIH AIDS Reagent Program
and stored frozen at an early passage. These cells are susceptible to R5 and X4 HIV-1 strains and express
-galactosidase and luciferase when infected by HIV. The early-passage cells used in this study exhibited
this susceptibility phenotype, helping to conﬁrm their authenticity. 293T/17 cells were obtained from the
ATCC and FreeStyle 293F cells from Thermo Fisher Scientiﬁc Inc. These cells have been kept frozen since
an early passage. 293F cells were successfully used to produce gp120, CD4-Ig, and some monoclonal
antibodies. 293T cells were used to express native HIV-1 Envs on the cell surface for CD4-Ig and antibody
binding assays as well as to produce HIV-1 Env pseudovirus stocks following transfection of appropriate
plasmid DNA constructs. The consistent high infectivity titers of these Env pseudoviruses produced
from 293T cells, which exhibit predicted Env tropisms and properties, help to verify their authenticity.
Preparation of soluble gp120 and CD4-Ig. Suspension 293F cells (1  106/ml in 500 ml) were
transfected with 250 g of DNA of pJW4303 containing different gp120s (48) using suspension 293Fectin
(Invitrogen Inc.) according to the manufacturer’s instructions. Transfected cells were cultured in Freestyle
293 expression medium (Invitrogen Inc.) in shaking ﬂasks for 72 h. Cells were then centrifuged out and
supernatants harvested before purifying gp120 over a lectin column. Then gp120s were concentrated
with 50,000 (50K)-molecular-weight (MW)-cutoff centrifugal ﬁlter concentrators (Millipore Inc.).
Similarly, 250 g of DNA of pcDM8 encoding CD4-Ig (53) was transfected into 293F cells (1  106/ml
in 500 ml) using suspension 293Fectin (Invitrogen Inc.). Following 3 days of culture, supernatant carrying
CD4-Ig was harvested, concentrated using tangential-ﬂow ﬁltration with a 70-kDa cutoff, and puriﬁed
with protein G Sepharose.
Soluble gp120/CD4 binding and afﬁnity measurements. Soluble gp120 binding to CD4-Ig was
investigated using a ForteBio Octet QKe platform according to the manufacturer’s instructions. This
approach exploits biolayer interferometry (BLI) measurements to detect binding in a 96-well plate format.
Protein A-coated biosensors were loaded with CD4-Ig (10 g/ml) in phosphate-buffered saline (PBS),
0.1% bovine serum albumin (BSA), 0.02% Tween 20, and 0.05% sodium azide. After capture, sensors were
washed in loading buffer to remove excess unbound CD4-Ig so that a new baseline signal was
established. The biosensors were then put into wells containing the different gp120 proteins at 2-fold
serially diluted concentrations from 300 to 18.8 nM in loading buffer for 10 min to measure binding rates
(kon). Sensors were then placed into wells containing loading buffer without gp120 to measure disso-
ciation over 10 min (koff). Equilibrium dissociation constant (KD) values were calculated as the ratio of koff
to kon values using the ForteBio Octet QKe data analysis software, package 7.1, via a 1:1 binding model
with the local ﬁtting function followed by the global ﬁtting function.
Expression and detection of Env trimers on 293T cells. A total of 2  105 293T cells were seeded
per well of 6-well plates the day before transfection. A transfection mix containing 25 g of DNA of each
of Env pSVIIIenv and pSV-tat72 together with 25 g of pFurin (27) with Fugene6 in Opti-MEM was
prepared to a total of 1.875 ml. This was sufﬁcient to transfect 12  105 293T cells according to the
manufacturer’s protocol.
Following 2 days of culture, transfected cells were detached using Versene and used for MAb staining
or CD4-IgG binding. A total of 0.5  106 cells were seeded into 96-well V-bottom plates and treated with
appropriate MAb or CD4-Ig concentrations in Dulbecco modiﬁed Eagle medium (DMEM) (4% fetal calf
serum [FCS]) for 40 min at 37°C. Cells were then washed in PBS and 1% FCS and treated with
goat-anti-human IgG-ﬂuorescein isothiocyanate (FITC) conjugate (Southern Biotech Inc.) for 40 min at
room temperature (RT), washed again in PBS, 1% FCS, and then PBS, and ﬁxed in 4% formaldehyde in
PBS. Fixed cells from each well were then ﬁltered through a 35-m ﬁlter-capped tube (Falcon Inc.) and
analyzed by ﬂow cytometry in the UMASS Medical School Flow Cytometry Core Lab. Experiments were
done in duplicate and at least twice, frequently multiple times. The results of one representative
experiment are presented, with duplicates shown. Fluorescence measurements for each Env varied in
different experiments due to differences in the efﬁciency of each transfection (of DNA clones for Env
expression). For these experiments, we were most concerned with variation in CD4-Ig binding rather
than transfection efﬁciency, so we did not compare results between experiments.
CD4-Ig is a chimeric molecule comprising part immunoglobulin and part CD4. CD4-Ig has two CD4
molecules (two domains each) and is therefore dimeric for CD4 (28). We also tested monomeric sCD4
(four domains) for its capacity to bind to mac-tropic B33 and non-mac-tropic LN40 Envs and obtained
results similar to those for CD4-Ig (Fig. 1C). This was achieved by staining with the CD4 MAb OKT4,
followed by a goat anti-mouse IgG-FITC conjugate (Southern Biotech Inc.). However, the assay using
sCD4 was less consistent and had higher background than that with CD4-Ig, probably due to the
additional layer of a mouse-anti-CD4 MAb that was required. We therefore persisted with assays using
CD4-Ig.
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Measurement of monoclonal antibody binding to gp120 by ELISA. The binding of MAbs 17b
(CD4i) and b6 (CD4bs) to gp120 was estimated using an ELISA protocol. ELISA data for MAbs b12 and
447-52D were taken from our previous publication (16).
Serial 2-fold dilutions of each MAb were added to captured gp120. A dilution of gp120 that saturated
the capture antibody was used throughout (54). Costar 96-well ELISA plates (Corning Inc.) were coated
with 250 ng/well of sheep anti-gp120 Ab D7324 (Aalto, Inc.) in phosphate-buffered saline (PBS). After
overnight incubation at RT, plates were washed twice with PBS–0.05% Tween, incubated for 2 h at RT
with blocking solution (3% bovine serum albumin in PBS), and washed four times with PBS–0.05%
Tween. Soluble gp120 (4 g/ml) was added for 120 min before washing 10 times and adding 2-fold
dilutions of 17b and b6 MAbs for 1 h at RT. After 10 washes, 50 l/well of goat anti-human immuno-
globulin G, F(ab=)2 fragment-speciﬁc calf intestinal alkaline phosphatase conjugate (Pierce Inc.) diluted
1:1,000 in dilution buffer was added to plates. After 1 h of incubation at RT, 50 l of 3,3=,5,5=-
tetramethylbenzidine (TMB) substrate (eBioscience Inc.) was added to each well before adding 2 M
sulfuric acid (stop solution) following color development. Plates were read at 492 nm, and EC50 values
were calculated using GraphPad Prism.
Preparation and titration of Env pseudoviruses. Env pSVIIIenv was cotransfected into 293T cells
with env pNL43. Env pseudovirions were harvested after 48 h, clariﬁed by low-speed centrifugation,
and frozen as aliquots at 152°C. Env pseudovirions were titrated on HeLa TZM-bl cells, which carry
-galactosidase and luciferase reporter genes controlled by HIV long terminal repeat (LTR) promoters
(49). Infected cells were visualized at 48 h after infection as focus-forming units (FFU) following staining
for -galactosidase activity. Since Env pseudovirions are capable of only a single round of replication,
individual cells or small groups of divided cells were counted as foci.
Neutralization assays. Neutralization assays were performed as described previously using HeLa
TZM-bl cells and a luminescence readout (16).
Accession number(s). The CA110 1-2 sequence has been deposited in GenBank under accession
number MF975654.
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